We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01699152
Recruitment Status : Completed
First Posted : October 3, 2012
Last Update Posted : May 6, 2016
Information provided by (Responsible Party):

Study Description
Brief Summary:
This is a multi-center, open-label, dose escalation study.

Condition or disease Intervention/treatment Phase
Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Drug: TG02 citrate Phase 1

Detailed Description:
The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Study Start Date : September 2012
Primary Completion Date : July 2015
Study Completion Date : May 2016

Arms and Interventions

Arm Intervention/treatment
Experimental: TG02 citrate
TG02 citrate capsules given orally.
Drug: TG02 citrate
TG02 citrate capsules
Other Name: No other names

Outcome Measures

Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: 28 days ]
    To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL.

Secondary Outcome Measures :
  1. Safety [ Time Frame: 28 days ]
    To assess the number of patients with adverse events as a measure of safety

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.
  • Patients must meet one or more of the following indications for treatment:

    1. Progressive disease or marked splenomegaly and/or lymphadenopathy.
    2. Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/μL).
    3. Unexplained weight loss exceeding 10% of body weight over the previous 6 months.
    4. CTCAE Grade 2 or 3 fatigue.
    5. Fevers >100.5º F or night sweats for more than 2 weeks without evidence of infection.
    6. Progressive lymphocytosis, with an increase exceeding 50% over a 2 month period or a doubling time of less than 6 months.
    7. Need for cytoreduction prior to allogeneic stem cell transplant.
  • Patients must have relapsed or refractory disease after ≥1 prior line of treatment.
  • The interval from prior treatment to time of study drug administration should be at least 5 half-lives for cytotoxic and noncytotoxic agents.
  • Low-dose corticosteroids (prednisone <20 mg/ day or equivalent dose) are permitted throughout study.
  • Clinically significant toxicities from prior chemotherapy must be resolved to Grade ≤ 1.
  • Age >18 years.
  • ECOG performance status ≤2.
  • Life expectancy ≥ 12 weeks.
  • Patients must have normal organ and marrow function as defined below:

    • absolute neutrophil count >1,000/μL in absence of bone marrow involvement
    • platelets ≥30,000/μL in absence of bone marrow involvement
    • If patient has extensive bone marrow involvement, minimum ANC and platelet levels are not required.
    • total bilirubin ≤1.5 X institutional ULN unless due to Gilbert's syndrome, controlled autoimmune hemolytic anemia or immune thrombocytopenia
    • AST(SGOT)/ALT(SGPT) <2.5 X institutional ULN unless due to disease
    • creatinine <2.0 mg/dL OR creatinine clearance >50 mL/min/1.73 m2
  • Negative serum or urine pregnancy test at the time of first dose for WOCBP.
  • Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for required assessments.
  • Ability to take oral medication.

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > 1) due to agents administered more than 3 weeks earlier.
  • Patients who have received prior treatment with a CDK inhibitor within 12 months of study enrollment.
  • High-dose corticosteroids (prednisone ≥20mg/day or equivalent dose) must be discontinued ≥ 7 days of initiating therapy.
  • Patients with known central nervous system involvement.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.
  • Patients with G6PD deficiency.
  • Concurrent severe or uncontrolled medical disease (including but not limited to history of ventricular arrhythmia or symptomatic conduction abnormality within 12 months, ongoing or active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
  • Pregnant and/or breast-feeding women.
  • Prior or second malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, or other cancer for which the subject has received curative therapy at least 3 years prior to study entry.
  • Known HIV or AIDs.
  • QTc interval prolongation >450ms for males and >470 ms for females.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01699152

United States, Georgia
Augusta, Georgia, United States, 30912
United States, Massachusetts
Boston, Massachusetts, United States, 02215
United States, Ohio
Columbus, Ohio, United States, 43210
United States, Tennessee
Nashville, Tennessee, United States, 37203
United States, Texas
Houston, Texas, United States, 77030
Sponsors and Collaborators
Tragara Pharmaceuticals, Inc.
Study Director: T Parrott Tragara Pharmaceuticals
More Information

Responsible Party: Tragara Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01699152     History of Changes
Other Study ID Numbers: TG02-102
First Posted: October 3, 2012    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: May 2016

Keywords provided by Tragara Pharmaceuticals, Inc.:
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Citric Acid
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action